Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
2022 | Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy | Lau, George; Yu, Ming-Lung; Wong, Grace; Thompson, Alexander; Ghazinian, Hasmik; Hou, Jin-Lin; Piratvisuth, Teerha; Jia, Ji-Dong; Mizokami, Masashi; Cheng, Gregory; Chen, Guo-Feng; Liu, Zhen-Wen; Baatarkhuu, Oidov; ANN-LII CHENG ; Ng, Woon Leung; Lau, Patrick; Mok, Tony; Chang, Jer-Ming; Hamid, Saeed; Dokmeci, A Kadir; Gani, Rino A; Payawal, Diana A; Chow, Pierce; Park, Joong-Won; Strasser, Simone I; Mohamed, Rosmawaiti; Win, Khin Maung; Tanwandee, Tawesak; Sarin, Shiv Kumar; Omata, Masao | Hepatology international | 0 | 0 | |
2019 | Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6) | Evans T.R.J.; Kudo M.; Finn R.S.; Han K.-H.; ANN-LII CHENG ; Ikeda M.; Kraljevic S.; Ren M.; Dutcus C.E.; Piscaglia F.; Sung M.W. | British Journal of Cancer | 2 | 2 | |
2017 | Corrigendum to “Degradation of Epidermal Growth Factor Receptor Mediates Dasatinib-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma Cells” [Neoplasia (United States) 14 (2012) 463–475](S1476558612801023)(10.1596/neo.12300) | Lin Y.-C.; Wu M.-H.; TZU-TANG WEI ; Chuang S.-H.; Chen K.-F.; ANN-LII CHENG ; CHING-CHOW CHEN | Neoplasia (United States) | 0 | 0 | |
2018 | Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008](S0168827817321347)(10.1016/j.jhep.2017.06.026)) | Bruix J.; ANN-LII CHENG ; Meinhardt G.; Nakajima K.; De Sanctis Y.; Llovet J. | Journal of Hepatology | 6 | 4 | |
2017 | Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2011) 55(5) (1041–1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047)) | Tai W.-T.; ANN-LII CHENG ; Shiau C.-W.; Huang H.-P.; Huang J.-W.; PEI-JER CHEN ; Chen K.-F. | Journal of Hepatology | 1 | 1 | |
2017 | Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2017) 66(3) (666–668) (S0168827816307127) (10.1016/j.jhep.2016.12.007)) | Tai W.-T.; ANN-LII CHENG ; Shiau C.-W.; Huang H.-P.; Huang J.-W.; PEI-JER CHEN ; Chen K.-F. | Journal of Hepatology | 0 | 1 | |
2020 | Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection | Tsou H.-H.; HUNG-CHIH YANG ; Hsiao C.-F; Hsiung C.A; Liu T.-W; Chuang M.-H; Wu H.-Y; Hsu Y.-T; Tsui C.-W; PEI-JER CHEN ; ANN-LII CHENG ; CHIUN HSU ; Taiwan Cooperative Oncology Group | Journal of the Formosan Medical Association | 8 | 8 | |
2019 | CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer | KUO-HSING CHEN ; LIANG-IN LIN ; LI-HUI TSENG ; Lin, Yu-Lin; JAU-YU LIAU ; JIA-HUEI TSAI ; JIN-TUNG LIANG ; BEEN-REN LIN ; ANN-LII CHENG ; KUN-HUEI YEH | Oncology | 6 | 4 | |
2012 | A Critical Evaluation of the Preventive Effect of Antiviral Therapy on the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C or B: A Novel Approach by Using Meta-Regression | YING-CHUN SHEN ; CHIUN HSU ; Cheng C.-C.; Hu F.-C.; ANN-LII CHENG | Oncology | 34 | 29 | |
2000 | Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis | Chuang S.E.; Kuo M.L.; CHIH-HUNG HSU ; Chen C.R.; Lin J.K.; Lai G.M.; CHANG-YAO HSIEH ; ANN-LII CHENG | Carcinogenesis | 240 | 210 | |
2022 | Current Status of the Spectrum and Therapeutics of Helicobacter pylori-Negative Mucosa-Associated Lymphoid Tissue Lymphoma | SUNG-HSIN KUO ; KUN-HUEI YEH ; CHUNG-WU LIN ; JYH-MING LIOU ; MING-SHIANG WU ; Chen, Li-Tzong; ANN-LII CHENG | Cancers | 9 | 8 | |
1992 | Cutaneous angiocentric T-cell lymphoma associated with Epstein-Barr virus | TSEN-FANG TSAI ; Su I.-J.; Lu Y.-C.; ANN-LII CHENG ; Yeh H.-P.; Hsieh H.-C.; HWEI-FANG TIEN ; JAU-SHIUH CHEN ; Uen W.-C. | Journal of the American Academy of Dermatology | 57 | 54 | |
1993 | Cutaneous manifestations of Epstein-Barr virus—associated T-cell lymphoma | Su I.-J.; TSEN-FANG TSAI ; ANN-LII CHENG ; Chen C.-C. | Journal of the American Academy of Dermatology | 64 | 57 | |
1990 | Cutaneous manifestations of postthymic T cell malignancies: Description of five clinicopathologic subtypes | Su I.-J.; Wu Y.-C.; YAO-CHANG CHEN ; Hsieh H.-C.; ANN-LII CHENG ; Wang C.-H.; Kadin M.E. | Journal of the American Academy of Dermatology | 39 | 35 | |
2016 | Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression | CHIUN HSU ; LIANG-IN LIN ; Cheng, Yu-Che; Feng, Zi-Rui; YU-YUN SHAO ; ANN-LII CHENG ; DA-LIANG OU | Clinical Cancer Research | 43 | 41 | |
2022 | Cyclin-Dependent Kinase 9 Inhibition as a Potential Treatment for Hepatocellular Carcinoma | YU-YUN SHAO ; Hsu, Hung-Wei; Wo, Rita Robin; Wang, Han-Yu; ANN-LII CHENG ; CHIH-HUNG HSU | Oncology | 3 | 3 | |
2013 | CYP19 genetic polymorphism haplotype aasa is associated with a poor prognosis in premenopausal women with lymph node-negative, hormone receptor-positive breast cancer | SUNG-HSIN KUO ; Yang, Shi-Yi; HUANG-CHUN LIEN ; Chiao Lo ; CHING-HUNG LIN ; YEN-SHEN LU ; ANN-LII CHENG ; KING-JEN CHANG ; CHIUN-SHENG HUANG | BioMed Research International | 9 | 9 | |
2016 | Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice | YI-HSIN LIANG ; YU-YUN SHAO ; BIN-CHI LIAO ; Lee, Ho-Sheng; CHIH-HSIN YANG ; Chen, Ho-Min; CHUN-JU CHIANG ; ANN-LII CHENG ; Lai, Mei-Shu | Journal of Cancer | 8 | 7 | |
2012 | Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells | Lin Y.-C.; Wu M.-H.; TZU-TANG WEI ; Chung S.-H.; Chen K.-F.; ANN-LII CHENG ; CHING-CHOW CHEN | Neoplasia (United States) | 37 | 36 | |
2022 | Deleterious alterations of DNA damage response and repair genes and clinical benefit to anti-PD-1 therapy in esophageal squamous cell carcinoma | JHE-CYUAN GUO ; CHIA-CHI LIN ; Hsu, Chia-Lang; TA-CHEN HUANG ; HUNG-YANG KUO ; Lin, Chen-Yuan; Lien, Ming-Yu; ANN-LII CHENG ; CHIH-HUNG HSU | Esophagus : official journal of the Japan Esophageal Society | 0 | 0 | |